CEL-SCI CORP (CVM) Stock Price, Quote, News and Overview
NYSEARCA:CVM - NYSE Arca - US1508376076 - Common Stock - Currency: USD
CVM Quote, Performance and Key Statistics
0.251
-0.02 (-5.64%)
The current stock price of CVM is 0.251 USD. In the past month the price increased by 26.19%. In the past year, price decreased by -84.6%.
CVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About CVM
Company Profile
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Company Info
CEL-SCI CORP
Suite 802, 8229 Boone Blvd .
Vienna VIRGINIA 22182 US
CEO: Geert Kersten
Employees: 44
Phone: 17035069460
CEL-SCI CORP / CVM FAQ
What is the stock price of CEL-SCI CORP today?
The current stock price of CVM is 0.251 USD. The price decreased by -5.64% in the last trading session.
What is the ticker symbol for CEL-SCI CORP stock?
The exchange symbol of CEL-SCI CORP is CVM and it is listed on the NYSE Arca exchange.
On which exchange is CVM stock listed?
CVM stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for CEL-SCI CORP stock?
6 analysts have analysed CVM and the average price target is 7.55 USD. This implies a price increase of 2907.17% is expected in the next year compared to the current price of 0.251. Check the CEL-SCI CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CEL-SCI CORP worth?
CEL-SCI CORP (CVM) has a market capitalization of 21.11M USD. This makes CVM a Nano Cap stock.
How many employees does CEL-SCI CORP have?
CEL-SCI CORP (CVM) currently has 44 employees.
What are the support and resistance levels for CEL-SCI CORP (CVM) stock?
CEL-SCI CORP (CVM) has a resistance level at 0.26. Check the full technical report for a detailed analysis of CVM support and resistance levels.
Should I buy CEL-SCI CORP (CVM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CVM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CVM, evaluating the profitability, health, valuation and growth aspects
- CEL-SCI CORP (CVM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CEL-SCI CORP (CVM) Sales and EPS estimates to see what analysts future expectations are.
- CEL-SCI CORP (CVM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CEL-SCI CORP (CVM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CEL-SCI CORP (CVM) Stock Chart to make your own analysis
- CEL-SCI CORP (CVM) Latest news and press-releases to stay up to date.
Does CEL-SCI CORP (CVM) stock pay dividends?
CVM does not pay a dividend.
When does CEL-SCI CORP (CVM) report earnings?
CEL-SCI CORP (CVM) will report earnings on 2025-05-13.
What is the Price/Earnings (PE) ratio of CEL-SCI CORP (CVM)?
CEL-SCI CORP (CVM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
What is the Short Interest ratio of CEL-SCI CORP (CVM) stock?
The outstanding short interest for CEL-SCI CORP (CVM) is 6.25% of its float. Check the ownership tab for more information on the CVM short interest.
CVM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CVM. When comparing the yearly performance of all stocks, CVM is a bad performer in the overall market: 96.46% of all stocks are doing better.
CVM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CVM. Both the profitability and financial health of CVM have multiple concerns.
CVM Financial Highlights
Over the last trailing twelve months CVM reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 28.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.73% | ||
| ROE | -247.1% | ||
| Debt/Equity | 0.66 |
CVM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CVM. The Buy consensus is the average rating of analysts ratings from 6 analysts.